WebJul 22, 2024 · Cisplatin is a potent and valuable chemotherapy agent used to treat a broad spectrum of malignancies. Renal tubular dysfunction and a cumulative impairment in … WebA, Progression-free survival (PFS) among 58 patients. B, Overall survival (OS) among 57 patients. The shaded regions represent 95% CIs. Figure 3. Change in Tumor Size From Baseline to Best Response Among 50 Patients in the Intention-to-Treat Population for Whom Data Were Available View LargeDownload Table.
HIGHLIGHTS OF PRESCRIBING INFORMATION - Food …
WebApr 14, 2024 · Among the extracellular vesicles, apoptotic bodies (ABs) are only formed during the apoptosis and perform a relevant role in the pathogenesis of different diseases. Recently, it has been demonstrated that ABs from human renal proximal tubular HK-2 cells, either induced by cisplatin or by UV light, can lead to further apoptotic death in … WebOct 5, 2014 · The lower excretion rate of carboplatin means that more is retained in the body, and hence its effects are longer lasting (a retention half-life of 30 hours for carboplatin, compared to 1.5-3.6 hours in the case of cisplatin). ... Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and ... educonnect education gouv fr aide
National Center for Biotechnology Information
WebApr 17, 2024 · Reported rates of cisplatin ototoxicity vary widely, though it is believed that at least half of all patients treated with cisplatin will suffer hearing loss. As cisplatin is widely used, this rate of ototoxicity translates to hundreds of thousands of patients affected each year in the United States alone. chemo, cancer, hearing loss WebThe oral vinorelbine-cisplatin combination with concurrent RT is feasible and has a favorable risk-benefit ratio in stage IIIA/IIIB NSCLC. ... In the intent-to-treat analysis, the response rates were 32.1% after induction CT and 41.1% after CT-RT. The median progression-free and overall survival times were 9.2 months (95% confidence interval: 7 ... WebJun 21, 2024 · At a median of 52 months of follow-up, the 3-year rates of event-free survival were 82% (95% CI, 69 to 90) in the cisplatin–sodium thiosulfate group and 79% (95% CI, 65 to 88) in the cisplatin ... educonnecct educat